RxDoctor Payments DataLook up a doctor →

Elizabeth Yeu-Lin, MD

Ophthalmology · Norfolk, VANPI 1740453620

Payments from drug & device makers

$2,023,587in general payments, 2019–2025

Across 708 payments — averaging $2858.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$720K
  • Alcon$333K
  • Johnson & Johnson Surgical Vision, Inc.$329K
  • Alcon Research LLC$250K
  • Carl Zeiss Meditec, Inc.$104K
  • Carl Zeiss Meditec Cataract Technology Inc.$99K
  • plus $190K from 29 others
$44,800in research payments, 2019–2025

Across 2 payments — averaging $22,400 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson Surgical Vision, Inc.$23K
  • Carl Zeiss Meditec Cataract Technology Inc.$22K

What the payments were for

  • Consulting fees$1,326,94478%
  • Speaking & faculty fees$344,18320%
  • Grants$3510%
  • Travel & lodging$14,4181%
  • Food & beverage$12,7751%
  • Education$4500%
  • Gifts$1,2560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,023,587 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$177,553
Medicare patients
233
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner29$52,930
Prednisolone Acetate59$4,070
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$2,152
Ketorolac Tromethamine55$1,603
Brimonidine Tartrate64$322
Tobramycin41$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$719,729$52,93029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →